0 avis
Comparison of blood tests for liver fibrosis specific or not to NAFLD
Archive ouverte
International audience.
Background/AimsTo compare blood tests of liver fibrosis specific for NAFLD: the FibroMeter NAFLD and the NAFLD fibrosis score (NFSA) with a non-specific test, APRI. Methods Two hundred and thirty-five NAFLD patients with liver Metavir staging and blood markers from two independent centres were randomly assigned to a test (n = 121) or a validation population (n = 114). Results The highest accuracy – 91% – for significant fibrosis was obtained with the FibroMeter whose (i) AUROC (0.943) was significantly higher than those of NFSA (0.884, p = 0.008) and APRI (0.866, p < 10−3; p = 0.309 vs NFSA) in the whole population, and (ii) misclassification rate (9%) was significantly lower than those of NFSA (14%, p = 0.04) and APRI (16%, p = 0.002) and did not vary according to centre (14 vs 7%, p = 0.07), unlike those of NFSA (25 vs 9%, p = 0.001) and APRI (29 vs 11%, p < 10−3). By using thresholds of 90% predictive values, liver biopsy could have been avoided in most patients: FibroMeter: 97.4% vs NFSA: 86.8% (p < 10−3) and APRI: 80.0% (p < 10−3). A new classification provided three reliable diagnosis intervals: F0/1, F0/1/2, F2/3/4 with 91.4% accuracy for FibroMeter, avoiding biopsy in all patients. Conclusions FibroMeter NAFLD had high performance and provided reliable diagnosis for significant fibrosis, significantly outperforming NFSA and APRI.
Consulter en ligne
Suggestions
Du même auteur
